Authors: Mitchell, DY Barr, WH Eusebio, RA Stevens, KAP Duke, FP Russell, DA Nesbitt, JD Powell, JH Thompson, GA

Citation: Dy. Mitchell et al., Risedronate pharmacokinetics and intra- and inter-subject variability uponsingle-dose intravenous and oral administration, PHARM RES, 18(2), 2001, pp. 166-170

Authors: Cox, KA Dunn-Meynell, K Korfmacher, WA Broske, L Nomeir, AA Lin, CC Cayen, MN Barr, WH

Citation: Ka. Cox et al., Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats, DRUG DISC T, 4(5), 1999, pp. 232-237

Authors: Sabatini, S Ferguson, RM Helderman, JH Hull, AR Kirkpatrick, BS Barr, WH

Citation: S. Sabatini et al., Drug substitution in transplantation: A National Kidney Foundation white paper, AM J KIDNEY, 33(2), 1999, pp. 389-397

Authors: Wu-Pong, S Livesay, V Dvorchik, B Barr, WH

Citation: S. Wu-pong et al., Oligonucleotide transport in rat and human intestine ussing chamber models, BIOPHARM DR, 20(9), 1999, pp. 411-416

Authors: Barr, WH

Citation: Wh. Barr, Cyclosporine: The case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets, TRANSPLAN P, 31(3A), 1999, pp. 25S-30S

Authors: Barr, WH

Citation: Wh. Barr, Scientific and professional concerns regarding product interchange and subsequent monitoring of cyclosporine and other critical dose drugs, TRANSPLAN P, 31(3), 1999, pp. 1645-1648